The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.
Biodesix will work with university researchers on an assay to help identify non-small cell lung cancer patients likely to respond to certain immunotherapies.
While the company has historically marketed the test's ability to predict patient drug response, it has more recently focused on its prognostic power.
The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.
GeneStrat is a blood-based test using a droplet digital PCR platform that detects mutations relevant to patient treatment in non-small cell lung cancer.
Positive Bioscience will offer Biodesix's liquid biopsy tests for non-small cell lung cancer in India.
According to a new study, the company returns results for more than 90 percent of its GeneStrat tests within 72 hours and aims to bring that down to 48 hours.
The test, which the company plans to launch later this year, will use MALDI-based proteomics to assess patients' likelihood of responding to immunotherapies.